AAIC 2025 Abstract·26 DecBaseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)Trial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecZervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p‐tau217 Across the Mild‐to‐Moderate AD SpectrumTrial in peopleInterventionsPaper